Convergence seeks partner for ex-GSK epilepsy asset
This article was originally published in Scrip
Executive Summary
Convergence Pharmaceuticals – a company predominately focused on the development of chronic pain drugs – has added an early stage epilepsy therapy to its pipeline, but it want to out-license it quickly.